{{scheme.chgp}}%
{{scheme.chgp}}%
No Matches Found
{{scheme.chgp}}%
No Matches Found
No Matches Found
C4 Therapeutics, Inc.
C4 Therapeutics, Inc. Hits New 52-Week High at $4.58
C4 Therapeutics, Inc. has achieved a new 52-week high of USD 4.58, despite a 1-year performance decline of 9.34%. With a market cap of USD 266 million, the company faces challenges, including a negative return on equity and a debt-to-equity ratio of -1.20, amidst a competitive biotechnology landscape.
C4 Therapeutics, Inc. Hits New 52-Week High at $3.96
C4 Therapeutics, Inc. has achieved a new 52-week high, reflecting a significant milestone in its performance despite a year marked by a decline in stock value. The company, with a market cap of USD 266 million, focuses on growth and currently operates at a loss, navigating challenges in the biotechnology sector.
Is C4 Therapeutics, Inc. technically bullish or bearish?
As of June 2, 2025, C4 Therapeutics, Inc. is in a mildly bearish trend, indicated by daily moving averages and weekly Bollinger Bands, despite some mixed signals from the MACD and KST indicators.
Who are in the management team of C4 Therapeutics, Inc.?
As of March 2022, the management team of C4 Therapeutics, Inc. includes Executive Chairman and Co-Founder Marc Cohen, President and CEO Andrew Hirsch, and Co-Founder and Director Ken Anderson.
What does C4 Therapeutics, Inc. do?
C4 Therapeutics, Inc. is a biopharmaceutical company focused on developing therapies that target and eliminate disease-causing proteins, primarily in cancer and neurodegenerative diseases. As of March 2025, it has a market cap of $105.80 million, with net sales of $7 million and a net loss of $26 million.
How big is C4 Therapeutics, Inc.?
As of Jun 18, C4 Therapeutics, Inc. has a market capitalization of 105.80 million and reported net sales of 39.79 million with a net profit loss of 103.28 million for the latest four quarters ending in March 2025.
{{list.post_title}}
{{list.post_excerpt}}
{{list.post_title}}
{{list.post_excerpt}}
